ONCO
Onconetix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.66
+15.69%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.55
From 52W high−99.57%
Volume1.03M
Market cap$3.45M
P/E (TTM)—
P/S (TTM)5.3x
Div yield—
Key dataNov 4, 2026
Open
$0.55
From 52W high
−99.57%
Volume
1.03M
Market cap
$3.45M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
52.2
MomentumView details →
1D Return
+15.69%
YTD Return
−99.23%
SummaryUpdated Jun 1, 2026
Onconetix, Inc. (NASDAQ:ONCO) is a biotechnology and pharmaceutical company founded in 2018 and headquartered in Cincinnati, Ohio. Originally incorporated as Blue Water Biotech, Inc., the company changed its name to Onconetix in December 2023. The company went public in February 2022 and focuses on developing and commercializing transformational therapies to address various health challenges worldwide. Onconetix operates in the biotechnology sector with a dual focus on commercializing existing FDA-approved treatments and developing innovative vaccine candidates for infectious diseases.
Similar companies
Latest newsMore news →
Onconetix announced that its board approved a one-for-ten reverse stock split of its outstanding common stock, expected to take effect on November 6, 2026.9d agoRealbotix LLC agreed to an additional US$500,000 advance under its bridge loan from Onconetix.12d agoSRX Global added a minority investment in Onconetix (Nasdaq: ONCO) ahead of the anticipated closing of the Realbotix LLC acquisition.41d ago